Mendus AB (publ) - Asset Resilience Ratio

Latest as of December 2025: 10.29%

Mendus AB (publ) (IMMU) has an Asset Resilience Ratio of 10.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Mendus AB (publ)'s equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr64.66 Million
≈ $6.96 Million USD Cash + Short-term Investments

Total Assets

Skr628.32 Million
≈ $67.62 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Mendus AB (publ)'s Asset Resilience Ratio has changed over time. See Mendus AB (publ) (IMMU) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Mendus AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Mendus AB (publ).

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr64.66 Million 10.29%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr64.66 Million 10.29%

Asset Resilience Insights

  • Moderate Liquidity: Mendus AB (publ) has 10.29% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Mendus AB (publ) Industry Peers by Asset Resilience Ratio

Compare Mendus AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Mendus AB (publ) (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Mendus AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 10.29% Skr64.66 Million
≈ $6.96 Million
Skr628.32 Million
≈ $67.62 Million
-4.34pp
2024-12-31 14.63% Skr101.91 Million
≈ $10.97 Million
Skr696.36 Million
≈ $74.94 Million
-1.34pp
2023-12-31 15.98% Skr120.78 Million
≈ $13.00 Million
Skr755.95 Million
≈ $81.35 Million
+9.23pp
2022-12-31 6.75% Skr41.85 Million
≈ $4.50 Million
Skr620.39 Million
≈ $66.76 Million
-14.80pp
2021-12-31 21.54% Skr155.31 Million
≈ $16.71 Million
Skr720.98 Million
≈ $77.59 Million
-1.47pp
2020-12-31 23.01% Skr167.64 Million
≈ $18.04 Million
Skr728.66 Million
≈ $78.42 Million
+18.53pp
2019-12-31 4.47% Skr13.59 Million
≈ $1.46 Million
Skr303.83 Million
≈ $32.70 Million
-94.27pp
2018-12-31 98.74% Skr444.70 Million
≈ $47.86 Million
Skr450.37 Million
≈ $48.47 Million
+46.61pp
2017-12-31 52.13% Skr128.32 Million
≈ $13.81 Million
Skr246.15 Million
≈ $26.49 Million
+44.29pp
2016-12-31 7.84% Skr9.53 Million
≈ $1.03 Million
Skr121.57 Million
≈ $13.08 Million
+1.68pp
2015-12-31 6.15% Skr9.49 Million
≈ $1.02 Million
Skr154.24 Million
≈ $16.60 Million
-43.72pp
2014-12-31 49.87% Skr35.43 Million
≈ $3.81 Million
Skr71.03 Million
≈ $7.64 Million
--
pp = percentage points

About Mendus AB (publ)

ST:IMMU Sweden Biotechnology
Market Cap
$41.55 Million
Skr386.09 Million SEK
Market Cap Rank
#22632 Global
#428 in Sweden
Share Price
Skr6.30
Change (1 day)
+14.55%
52-Week Range
Skr3.96 - Skr10.02
All Time High
Skr737.49
About

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more